Browsing by Author "Gabel, Leigh"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemOpen AccessBone health and physical activity in adolescents with juvenile idiopathic arthritis: a cross-sectional case-control study(2024-04-19) Vasil, Egi; M. Nesbitt, Colleen; Toomey, Clodagh; Kuntze, Gregor; Esau, Shane; A. Emery, Carolyn; Gabel, LeighAbstract Background Adolescents with juvenile idiopathic arthritis (JIA) tend to engage in less physical activity than their typically developing peers. Physical activity is essential for bone development and reduced physical activity may detrimentally effect bone health. Thus, we examined differences in total body bone mineral content (BMC) and areal bone mineral density (aBMD) between adolescents with JIA and adolescent controls without JIA. We also examined associations between moderate-to-vigorous physical activity (MVPA), lean mass, and bone outcomes. Methods Participants included 21 adolescents with JIA (14 females, 7 males) and 21 sex- and age-matched controls aged 10–20 years. Assessments included: height; weight; triple-single-leg-hop distance (TSLH); MVPA by accelerometry; and total body BMC, aBMD, and lean mass measured using dual X-ray absorptiometry. Height-adjusted z-scores were calculated for BMC and aBMD and used for all analyses. Multiple linear mixed effects models examined group differences in BMC and aBMD, adjusting for sex, maturity, MVPA, TSLH, and lean mass. Participants clusters, based on sex and age (within 18 months), were considered random effects. Results Adolescents with JIA had lower total body aBMD z-scores [β (95% CI); -0.58 (-1.10 to -0.07), p = 0.03] and BMC z-scores [-0.47 (-0.91 to -0.03), p = 0.04] compared with controls. Mean daily MVPA was 22.0 min/day lower in adolescents with JIA than controls; however, MVPA was not associated with aBMD [-0.01 (-0.01 to 0.01), p = 0.32] or BMC [0.00 (-0.01 to 0.00), p = 0.39]. Lean mass was positively associated with aBMD [0.05 (0.01 to 0.09) g/cm2, p = 0.03] and BMC [0.06 (0.03 to 0.10) g, p < 0.001]. Conclusion Adolescents with JIA had lower total body aBMD and BMC compared with sex- and age-matched controls without JIA. Group differences in bone outcomes were not associated with the lower MVPA participation of adolescents with JIA. Despite this, physical activity should still be encouraged as it promotes physical well-being.
- ItemEmbargoBone Loss and Fracture Risk Following Spinal Cord Injury: Patient Priorities and Treatment Options(2024-04-22) Crack, Laura Elizabeth; Edwards, W. Brent; Gabel, Leigh; Kline, GregRapid and profound bone loss is a well-known secondary complication following spinal cord injury (SCI), occurring primarily below the level of neurological lesion due to mechanical disuse. The greatest loss of bone is experienced during the acute phase of injury, and established osteoporosis often persists into the chronic phase, with no current standard care plan for patients. The main goals of this thesis were to: (1) explore patient knowledge and awareness regarding bone loss, fracture risk and treatment options following SCI, and (2) to investigate pharmaceutical treatment options to prevent bone loss in acute SCI, as well as treat established osteoporosis in chronic SCI. Three independent studies were carried out and are presented in Chapters 3-5, respectively. Survey results demonstrated that while more than half of participants with SCI were able to correctly answer knowledge-based questions regarding bone health, less than one-fifth had received education on the topic, and approximately three-quarters were interested in learning more about treatment options. Our clinical trials demonstrated the efficacy of zoledronic acid (antiresorptive therapy) to mitigate loss of bone mineral and strength at the hip in acute SCI, regardless of one’s ability to regain ambulation following injury, and the efficacy of romosozumab (anabolic and antiresorptive monoclonal antibody therapy) to increase bone mineral and strength at the hip, but not the knee, in women with chronic SCI. These findings add to the existing body of literature suggesting zoledronic acid is a strong candidate for standard of care to mitigate bone loss during acute SCI, and indicating that further investigation is required to find a treatment that can increase bone mineral, and reduce fracture risk, at both the hip and knee during chronic SCI for those with established osteoporosis.